INT87741

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.60
First Reported 2000
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 5
Disease Relevance 4.77
Pain Relevance 0.50

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Msr1) plasma membrane (Msr1)
Anatomy Link Frequency
hearts 1
Msr1 (Mus musculus)
Pain Link Frequency Relevance Heat
Somatostatin 4 100.00 Very High Very High Very High
Pain 5 98.24 Very High Very High Very High
tolerance 2 97.56 Very High Very High Very High
imagery 2 81.44 Quite High
Morphine 4 75.00 Quite High
Cancer pain 3 75.00 Quite High
depression 1 59.04 Quite High
ischemia 12 41.60 Quite Low
colic 1 25.00 Low Low
Inflammation 5 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Targeted Disruption 65 99.98 Very High Very High Very High
Diabetes Mellitus 152 99.50 Very High Very High Very High
Myeloid Leukemia 25 99.20 Very High Very High Very High
Cancer 3 99.08 Very High Very High Very High
Supranuclear Palsy 6 98.28 Very High Very High Very High
Pain 3 98.24 Very High Very High Very High
Pituitary Cancer 4 92.44 High High
Thyroid Disease 3 88.24 High High
Hypertension 3 84.68 Quite High
Ataxia 19 75.56 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Fourteen studies compared oral sustained release morphine (MSR) preparations with immediate release morphine (MIR).
Localization (release) of MSR
1) Confidence 0.60 Published 2003 Journal Cochrane Database Syst Rev Section Body Doc Link 14583997 Disease Relevance 0.05 Pain Relevance 0
In diabetic Tg DN PPET RAGE, and Tg DN MSR RAGE mice hearts, concentrations of CML, furosine, and pentosidine were similar to those in diabetic wild-type hearts (Table 2).
Localization (hearts) of DN MSR in hearts associated with targeted disruption, myeloid leukemia and diabetes mellitus
2) Confidence 0.20 Published 2008 Journal Diabetes Section Body Doc Link PMC2453611 Disease Relevance 3.08 Pain Relevance 0
OBJECTIVE: To compare the efficacy, safety and pharmacokinetics of a newly developed controlled-release suppository (MSR) with MS Contin tablets (MSC) in cancer patients with pain.
Localization (release) of MSR associated with pain and cancer
3) Confidence 0.12 Published 2000 Journal Eur. J. Clin. Pharmacol. Section Abstract Doc Link 10952476 Disease Relevance 0.27 Pain Relevance 0.25
The present study was performed to evaluate the effects of a slow release formulation of the somatostatin analog lanreotide (SR-L) on both hormone secretion and tumor size and to assess the tolerance in a series of thyrotropinomas treated for 6 months.
Localization (release) of SR-L associated with cancer, tolerance and somatostatin
4) Confidence 0.05 Published 2000 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 10770186 Disease Relevance 0.44 Pain Relevance 0.22
III) for six weeks made use of MRS as a noninvasive measure of indices of metabolic function.
Localization (use) of MRS
5) Confidence 0.05 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2785862 Disease Relevance 0.93 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox